GE HealthCare will unveil several imaging innovations and will offer new immersive experiences at ECR 2023, which begins in Vienna on March 1, the company said.
A Care Pathway Experience with an interactive gaming component will be offered to challenge visitors on a variety of patient cases and an Emergency Department Experience will be offered that focuses on how staff can tackle increasing pressures.
The company will showcase its One-Stop Clinic for Breast as well as the Ultrasound and Invenia ABUS Clinical Education Workshops. Also, with Imaging 360 for Operations, the company will launch an operational hub that features a 360° view that enables radiology departments to make data-driven decisions to improve outcomes.
In addition, the company will be offering the following sessions, symposia, and interactive experiences, exclusively in Auditorium E2 on Level 0:
- The Future of Healthcare with Rob Walton, president and CEO, GE HealthCare EMEA (March 1, 15:00 CET)
- A clinical debate: Optimizing imaging in chest-pain patients (March 1, 13:00 CET)
- Advanced diagnostic capabilities in MR imaging for all ages (March 2, 12:30 CET)
- Digital Transformation in Healthcare - A data-driven future (March 2, 16:00 CET)
- The limitless future of CT: Advanced clinical capabilities in Cardiac and Emergency (March 3, 12:30 CET)
- An end-to-end approach to prostate cancer care (March 3, 16:00 CET)
ECR 2023 will be the first time that GE HealthCare will participate in ECR as an independent publicly traded company after its spin-off from GE.
![Images show the pectoralis muscles of a healthy male individual who never smoked (age, 66 years; height, 178 cm; body mass index [BMI, calculated as weight in kilograms divided by height in meters squared], 28.4; number of cigarette pack-years, 0; forced expiratory volume in 1 second [FEV1], 97.6% predicted; FEV1: forced vital capacity [FVC] ratio, 0.71; pectoralis muscle area [PMA], 59.4 cm2; pectoralis muscle volume [PMV], 764 cm3) and a male individual with a smoking history and chronic obstructive pulmonary disorder (COPD) (age, 66 years; height, 178 cm; BMI, 27.5; number of cigarette pack-years, 43.2, FEV1, 48% predicted; FEV1:FVC, 0.56; PMA, 35 cm2; PMV, 480.8 cm3) from the Canadian Cohort Obstructive Lung Disease (i.e., CanCOLD) study. The CT image is shown in the axial plane. The PMV is automatically extracted using the developed deep learning model and overlayed onto the lungs for visual clarity.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/03/genkin.25LqljVF0y.jpg?auto=format%2Ccompress&crop=focalpoint&dpr=2&fit=crop&h=167&q=70&w=250)
